BBIO: BridgeBio Pharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 6,437.88
Enterprise Value ($M) 7,488.46
Book Value ($M) -1,457.61
Book Value / Share -7.66
Price / Book -4.42
NCAV ($M) -1,656.26
NCAV / Share -8.71
Price / NCAV -3.89

Profitability (mra)
Return on Invested Capital (ROIC) -1.93
Return on Assets (ROA) -0.63
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 5.33
Current Ratio 5.33

Balance Sheet (mrq) ($M)
Current Assets 720.69
Assets 919.34
Liabilities 2,376.95
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 221.90
Operating Income -577.37
Net Income -535.76
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -520.73
Cash from Investing 60.78
Cash from Financing 748.46

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
03-12 13D/A Viking Global Investors Lp 11.70 0.00
03-07 13D/A KKR Genetic Disorder L.P. 10.10 -23.75
02-13 13G/A Kumar Neil 5.41 5.09
11-12 13G/A BlackRock, Inc. 6.80 0.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-20 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 487,857 1,241,506 39.30
2025-04-16 839,119 1,869,586 44.88
2025-04-15 224,621 1,281,045 17.53
2025-04-14 359,243 1,184,052 30.34

(click for more detail)

Similar Companies
ATRA – Atara Biotherapeutics, Inc. AVIR – Atea Pharmaceuticals, Inc.
AVXL – Anavex Life Sciences Corp. BCRX – BioCryst Pharmaceuticals, Inc.
BDTX – Black Diamond Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io